- Cat. No.
- A11018
Fasiglifam (TAK-875)
Synonyms: TAK875
TAK-875 is a potent, selective, and orally bioavailable GPR40 agonist.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Free fatty acid receptor (FFAR) ligands act on G protein-coupled receptors (GPCRs) that sense fatty acids. FFAR1 and FFAR4, also called G protein-coupled receptors 40 and 120 (GPR40, GPR120), respond to medium- and long-chain fatty acids. FFAR2 and FFAR3 are GPCRs that instead bind short-chain fatty acids produced by gut bacteria. In 2003 GPR40 was shown to mediate fatty acid-stimulated insulin secretion from pancreatic beta cells. Two years later, GPR120 was linked to fatty acid-induced secretion of glucagon-like peptide 1 (GLP-1) in the gut. Fasiglifam, TUG-770 and LY2922470 are FFAR1 agonists, and GW-1100 is an FFAR1 antagonist. TUG-891 is an FFAR4 agonist, whereas GW9508 acts on both FFAR1 and FFAR4.
Synonyms: TAK875
TAK-875 is a potent, selective, and orally bioavailable GPR40 agonist.
GW-1100 is a selective GPR40 antagonist with a pIC50 of 6.9.
GW 9508 is a cell-permeable aminophenylpropanoate that acts as a potent and selective agonist for the G-protein coupled receptor (GPCR) GRP40/FFA1 receptor (EC50 ?50 nM) with reduced activity towards family members GRP120 (EC50 ?3.5 μM), GRP41/GRP43 (EC50 >50 μM), as well as a panel of eight other free fatty acid (FFA) and prostaglandin receptors.
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively.
TUG-770 is a Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.
Synonyms: AMG-837
AMG-837 calcium hydrate is a potent, orally bioavailable GPR40 agonist.
GSK137647A is a selective FFA4 agonist, with pEC50 of 6.3, 6.2, and 6.1 for human, Mouse and Rat FFA4, respectively.
GPR120 modulator 1 is useful for modulating G protein-coupled receptor 120 (GPR120).
GPR120 modulator 2 is useful for modulating G protein-coupled receptor 120 (GPR120).
TUG-891 is a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), which demonstrates both potential opportunity and possible challenges to therapeutic agonism.
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pKi of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ.
GPR40 agonist 1 is a potent and novel GPR40 full agonist with an EC50 of 2 nM and 17 nM for hGPR40 and rGPR40, respectively.
GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.
Synonyms: GPR120
Grifolic acid is a selective partial agonist of GPR120 that induces ERK activation and intracellular calcium responses in mouse enteroendocrine STC-1 cells.
GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate.
AP5 exhibits potent and selective agonism for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC50 of 0.49±0.28 nM against the GPR40 receptor.
GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1).
GPR120-IN-1 is a selective Gpr120 agonist with a logEC50 of ?7.62.
Synonyms: PBI-4050 sodium salt; PBI4050
Setogepram sodium salt (PBI-4050 sodium salt) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84.
GPR40 Activator 1 is a potent GPR40 activator for treatment of type 2 diabetes.
AMG 837 is a potent GPR40 agonist (EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.
GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC50 of 9 nM.
AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC50 of 0.16 μM.
GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1.